title: [Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France].
abstract: The international phase IIIb study, ATHENA assessed the combination of bevacizumab/taxane-based chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (mBC) in real-life setting. Among the 365 patients included in France, median overall survival (OS) is 28.4 months (CI95% 24.8-33.0), with a median time from treatment start to end of study of 36,5 months (25,1-45,4). Exploratory analyses in three sub-groups show that the median OS in long responder patients (not progressing for at least one year; n = 116) is not reached. In responder patients (n = 308), median OS is 33.0 months (CI95% 28.6-37.4) and 12.4 months (CI95% 11.2-17.4) in non-responders (n = 41). In patients with mBC expressing hormone receptors (HR+), treated with first-line hormone therapy before inclusion (n = 87) median OS in is 23.2 months (CI95% 19.6-28.6), and 35.3 months (CI95% 32.2-not reached); P = 0.004 in patients treated first with chemotherapy + bevacizumab (n = 179). The safety analysis in the various sub-groups of grade 3-5 adverse events of particular interest to bevacizumab of this study was comparable to the safety data of randomized phase III studies.
authors.affiliation: Université Paris-Descartes, Institut Curie, Département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Pierga
authors.affiliation: Centre Paul-Papin, 2, rue Moll, 49000 Angers, France.
authors.forename: Rémy
authors.initials: R
authors.lastname: Delva
authors.affiliation: CHU Jean-Minjoz, 3, boulevard Alexandre-Fleming, 25030 Besançon, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pivot
authors.affiliation: Hôpital Saint-Louis, 1 avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Espié
authors.affiliation: Institut Claudius-Regaud, 20-24, rue du Pont Saint-Pierre, 31300 Toulouse, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Dalenc
authors.affiliation: Institut Sainte-Catherine, 250, chemin de Baigne-Pieds, 84918 Avignon, France.
authors.forename: Daniel
authors.initials: D
authors.lastname: Serin
authors.affiliation: Centre Henri-Becquerel, rue d'Amiens, 76038 Amiens, France.
authors.forename: Corinne
authors.initials: C
authors.lastname: Veyret
authors.affiliation: Centre Catherine de Sienne, 2, rue Éric-Tabarly, 44202 Nantes, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Lortholary
authors.affiliation: Hôpital Tenon, 4, rue de la Chine, 75020 Paris, France.
authors.forename: Joseph
authors.initials: J
authors.lastname: Gligorov
authors.affiliation: Lincoln, 4, rue Danjou, 92517 Boulogne-Billancourt, France.
authors.forename: Katelle
authors.initials: K
authors.lastname: Joly
authors.affiliation: Laboratoires Roche, 30, cours de l'Île Seguin, 92650 Boulogne-Billancourt, France.
authors.forename: Juana
authors.initials: J
authors.lastname: Hernandez
authors.affiliation: Clinique armoricaine de radiologie, 21, rue du Vieux-Séminaire, 22000 Saint-Brieuc, France.
authors.forename: Anne-Claire
authors.initials: AC
authors.lastname: Hardy-Bessard
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D001952:Bridged-Ring Compounds / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D005602:France; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D001952:Bridged-Ring Compounds; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D042461:Vascular Endothelial Growth Factor A; C080625:taxane
keywords: bevacizumab; first-line; metastatic breast cancer; sub-groups; survival